<DOC>
	<DOCNO>NCT02342548</DOCNO>
	<brief_summary>This study 12 month open label extension study PF-02545920 20 mg dose BID follow study A8241021 subject HD . Primary endpoint assess long-term safety tolerability 20 mg BID PF-02545920 . Secondary endpoint change baseline Total Motor Score ( TMS ) assessment , and/ior Total maximum Chorea ( TMC ) assessment Unified Huntington Disease Rating Scale ( UHDRS ) 6 12 month treatment , Clinical Global Impression-Improvement score 6 12 month treatment . Subjects , assign 20 mg PF-02545920 dose group precede A8241021 study , receive 20 mg PF-02545920 without titration . All subject titrate 20 mg BID dose follow : 5 mg BID 7 day , 10 mg BID 7 day , 15 mg BID 7 day , 20 mg BID remainder treatment phase . Up 260 subject may take part open label extension</brief_summary>
	<brief_title>Open Label Extension Study To Investigate Long Term Safety , Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington 's Disease Who Completed Study A8241021</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Subjects must complete study A8241021 Diagnosis HD , include ≥36 CAG repeat . Significant neurological disorder Huntington 's disease . WBC ≤ 3500/mm3 AND/OR ANC ≤ 2000/mm3 history neutropenia myeoloproliferative disorder . Any drug relate SAE experience study A8241021 approve acceptable enrollment A8241022 .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Huntington ; chorea ; total motor score ; CAG repeat : total functional capacity ; motor cognitive behavioral symptom</keyword>
</DOC>